Signing a deal with a large pharma player in the form of Johnson & Johnson for its lead type I diabetes product is not so much the validation that Diamyd Medical needed, but perhaps a logical conclusion and justified reward to the group’s impressive efforts to advance the immunotherapy through the clinic. The company has taken the drug into phase III trials not only single-handedly but with the kind of R&D spend that should make more profligate companies blush. Yesterday, the Stockholm-based company announced that J&J had taken an option to license the product, a novel vaccine for type I diabetes, which also shares its name with the company, resulting in the payment of an upfront fee of $45m and potential milestones of $580m. The news triggered a 28% jump in the group’s share price to SKr139, close to the record high of SKr151.50 achieved in March; the stock has more than tripled in value in the last 12 months.
This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: email@example.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
Terms & Conditions